Loading
Metabolism and Genetic Disorders · Journal article
Journal of Education Health and Sport · July 9, 2026
Raises a question worth testing. It does not answer one.
This narrative review summarizes proposed neurobiochemical mechanisms by which ketone bodies and ketogenic diet might exert neuroprotective, anti-inflammatory, and neuromodulatory effects in selected neurodegenerative and psychiatric disorders. The authors acknowledge that despite encouraging mechanistic observations, large-cohort randomized trials remain necessary before clinical implementation, and the evidence presented is insufficient to change current practice.
Narrative review. Patients with selected neurodegenerative diseases (Alzheimer's disease, Parkinson's disease) and psychiatric disorders (bipolar disorder, schizophrenia, treatment-resistant depression). Intervention: Ketogenic diet as metabolic therapy.
β-hydroxybutyrate crosses the blood-brain barrier via monocarboxylate transporters and may bypass neuronal insulin resistance implicated in Alzheimer's disease BHB may inhibit the NLRP3 inflammasome, potentially reducing proinflammatory cytokine release Ketosis may stimulate glutamic acid decarboxylase activity, shifting neurotransmitter balance toward GABAergic transmission relevant to mood stabilization
No comparison of ketogenic diet to standard pharmacotherapy or other interventions
Clinicians should recognize ketogenic diet as a mechanistically plausible but unproven adjuvant strategy. Implementation is not yet supported by large-scale clinical trials and should remain investigational pending rigorous controlled evidence in each target disorder.
A narrative review of mechanistic pathways and preliminary clinical observations that raises questions about ketogenic diet potential rather than answering them with controlled trial evidence.
As stated by the source record.
Clinicians should recognize ketogenic diet as a mechanistically plausible but unproven adjuvant strategy. Implementation is not yet supported by large-scale clinical trials and should remain investigational pending rigorous controlled evidence in each target disorder.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Pharmacoresistance in central nervous system (CNS) pathologies remains a major clinical challenge. The ketogenic diet (KD) is emerging as a potential multimodal metabolic therapy. Ketone bodies appear to remodel neuronal bioenergetics and modulate neurotransmission, laying the groundwork for the developing field of metabolic psychiatry. Aim & Methods: This narrative review (2010–2026) evaluates the neurobiochemical mechanisms of ketone bodies and the potential of the KD as an adjuvant intervention in selected neurodegenerative (Alzheimer's, Parkinson's) and psychiatric (bipolar disorder, schizophrenia, treatment-resistant depression) conditions. Results: Evidence suggests that β-hydroxybutyrate (BHB) crosses the blood-brain barrier via monocarboxylate transporters to fuel the tricarboxylic acid cycle, potentially bypassing the neuronal insulin resistance—often termed type 3 diabetes—implicated in Alzheimer's disease. At the cellular level, BHB may exert neuroprotective effects by inhibiting the NLRP3 inflammasome, which appears to reduce the release of proinflammatory cytokines. Furthermore, ketosis is associated with amino acid pathway remodeling; it may stimulate glutamic acid decarboxylase (GAD) activity, potentially shifting the neurotransmitter balance toward inhibitory GABAergic transmission relevant to mood stabilization. Additionally, BHB acts as an endogenous histone deacetylase (HDAC) inhibitor, which might upregulate brain-derived neurotrophic factor (BDNF) expression and facilitate neurogenesis. Conclusions: The KD is a promising neurometabolic intervention that may target underlying CNS pathomechanisms through mitochondrial optimization, anti-inflammatory effects, and epigenetic modifications. Despite encouraging initial reports, widespread implementation requires strict metabolic monitoring. Large-cohort randomized trials remain necessary before integrating ketogenic protocols into standard neuro-psychiatric treatment algorithms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.